FDA OKs Continued Enrollment in Ongoing Blood Cancer Clinical Trials After Gilead Addresses Safety Concerns
April 15th, 2022
Earlier in the year, clinical trials assessing magrolimab for myelodysplastic syndrome and acute myeloid leukemia were put on a partial clinical hold, but now the FDA said that they can start enrolling patients again.